BioCentury | Jan 27, 2021
Emerging Company Profile

Nuvalent: Structure-based design to address selectivity, tumor resistance

After more than three years in stealth mode during which it subsisted on a $50 million series A round from Deerfield, Nuvalent is headed into the clinic with two targeted programs for non-small cell lung...
BioCentury | May 4, 2018
Politics & Policy

Jury convicts Blaszczak, Deerfield partners of insider trading

...information and using it for illegal trading. The jury convicted political intelligence consultant David Blaszczak; Deerfield partners...
BioCentury | Nov 17, 2017
Company News

Deerfield partners with Johns Hopkins to fund early stage discovery

On Nov. 16, Deerfield Management announced a new $65 million JV that will commercialize early stage discovery projects with The Johns Hopkins University, in a deal modeled on last month's pact with the Broad Institute...
BioCentury | Feb 3, 2017
Targets & Mechanisms

Eating healthy

While pharma is still treading carefully in the field of autophagy, unsure of its use in cancer, Deerfield Management Corp. L.P. has decided the time is right to invest in the emerging translational opportunities. The...
BioCentury | Apr 6, 2015
Financial News

aTyr completes venture financing

...2015-03-31 Type: Venture financing Raised: $76 million Investors: Sofinnova Ventures; T. Rowe Price; Federated Investors; Deerfield Partners...
BioCentury | Jul 21, 2014
Company News

Intezyne management update

...Inc. , Tampa, Fla. Business: Cancer Hired: Tim Coan as CFO, formerly a partner at Deerfield Partners...
BioCentury | Jun 4, 2013
Clinical News

Array's selumetinib meets in Phase II ocular melanoma

...use the majority of the proceeds to repay the balance of a debt facility from Deerfield Partners...
BioCentury | Apr 1, 2013
Finance

Back for thirds

...the company (see BioCentury, Jan. 16, 2012) . bluebird's round last year included hedge fund Deerfield Partners...
BioCentury | Jul 30, 2012
Financial News

bluebird bio completes venture financing

...Business: Gene/Cell therapy, Hematology, Neurology Date completed: 7/25/12 Type: Venture financing Raised: $60 million Investors: Deerfield Partners...
BioCentury | Jul 30, 2012
Finance

Blue skies for bluebird

...Blue skies for bluebird Deerfield Partners made a rare investment in a private company last week when...
Items per page:
1 - 10 of 19
BioCentury | Jan 27, 2021
Emerging Company Profile

Nuvalent: Structure-based design to address selectivity, tumor resistance

After more than three years in stealth mode during which it subsisted on a $50 million series A round from Deerfield, Nuvalent is headed into the clinic with two targeted programs for non-small cell lung...
BioCentury | May 4, 2018
Politics & Policy

Jury convicts Blaszczak, Deerfield partners of insider trading

...information and using it for illegal trading. The jury convicted political intelligence consultant David Blaszczak; Deerfield partners...
BioCentury | Nov 17, 2017
Company News

Deerfield partners with Johns Hopkins to fund early stage discovery

On Nov. 16, Deerfield Management announced a new $65 million JV that will commercialize early stage discovery projects with The Johns Hopkins University, in a deal modeled on last month's pact with the Broad Institute...
BioCentury | Feb 3, 2017
Targets & Mechanisms

Eating healthy

While pharma is still treading carefully in the field of autophagy, unsure of its use in cancer, Deerfield Management Corp. L.P. has decided the time is right to invest in the emerging translational opportunities. The...
BioCentury | Apr 6, 2015
Financial News

aTyr completes venture financing

...2015-03-31 Type: Venture financing Raised: $76 million Investors: Sofinnova Ventures; T. Rowe Price; Federated Investors; Deerfield Partners...
BioCentury | Jul 21, 2014
Company News

Intezyne management update

...Inc. , Tampa, Fla. Business: Cancer Hired: Tim Coan as CFO, formerly a partner at Deerfield Partners...
BioCentury | Jun 4, 2013
Clinical News

Array's selumetinib meets in Phase II ocular melanoma

...use the majority of the proceeds to repay the balance of a debt facility from Deerfield Partners...
BioCentury | Apr 1, 2013
Finance

Back for thirds

...the company (see BioCentury, Jan. 16, 2012) . bluebird's round last year included hedge fund Deerfield Partners...
BioCentury | Jul 30, 2012
Financial News

bluebird bio completes venture financing

...Business: Gene/Cell therapy, Hematology, Neurology Date completed: 7/25/12 Type: Venture financing Raised: $60 million Investors: Deerfield Partners...
BioCentury | Jul 30, 2012
Finance

Blue skies for bluebird

...Blue skies for bluebird Deerfield Partners made a rare investment in a private company last week when...
Items per page:
1 - 10 of 19